Added to YB: 2026-06-15
Pitch date: 2026-06-10
BMY [neutral]
Bristol-Myers Squibb Company
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Market Cap
$116.7B
Pitch Price
N/A
Price Target
N/A
Dividend
4.41%
EV/EBITDA
7.85
P/E
16.00
EV/Sales
3.14
Sector
Pharmaceuticals
Category
growth
Show full summary:
GS Healthcare Conference – Recap (Day 2 – Part 2) - Bristol-Myers Squibb Company
BMY (overview): At $56.32, executing well toward upper-end guidance, rebuilding portfolio beyond upcoming LOEs. Oncology: 20+ combo studies, Pumitamig (PD-L1/VEGF bispecific), Iberdamide Aug 17 PDUFA in MM/MRD. Milvexion AFib data Q4'26. Cobenfy neuro rebuild, Admiral Barron Ph3 fibrosis.
Read full article (1 min)